The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis



Status:Recruiting
Conditions:Neurology, Neurology, Multiple Sclerosis
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:18 - 60
Updated:10/21/2017
Start Date:September 2014
End Date:January 2019
Contact:Joan Nye, BS
Email:joan.nye@yale.edu
Phone:(203) 737-7095

Use our guide to learn which trials are right for you!

The purpose of this work is to investigate the influence of dietary salt intake on immune
function in multiple sclerosis (MS) subjects and healthy controls. This study primarily tests
the hypothesis that higher dietary salt intake will be associated with a higher frequency of
pathogenic Th17 cells and impaired function of protective regulatory T cells. If a
relationship between dietary salt intake and immune function is observed, this study will
also test: a) whether this relationship is unique to MS subjects or whether it is also
present in healthy controls, and b) whether healthier immune function can be restored by
restricting dietary salt intake.

The purpose of this work is to investigate the influence of dietary salt intake on immune
function in MS subjects and healthy controls. This study primarily tests the hypothesis that
higher dietary salt intake will be associated with a higher frequency of pathogenic Th17
cells and impaired function of protective regulatory T cells. If a relationship between
dietary salt intake and immune function is observed, this study will also test: a) whether
this relationship is unique to MS subjects or whether it is also present in healthy controls,
and b) whether healthier immune function can be restored by restricting dietary salt intake.
This is a 5-week pilot study of a dietary intervention of 25 subjects with MS or Clinically
Isolated Syndrome (CIS) by 2010 Diagnostic Criteria who will be identified and recruited from
the Yale MS Center and/or referred from outside MS centers. 25 age-matched healthy controls
will be recruited from friends, family members, spouses and the patient waiting room at the
Yale MS Center.

Inclusion Criteria:

- Male or Female adult subjects

- Ages 18-60, inclusive

- diagnosis of CIS or MS by 2010 McDonald Criteria (in the case of MS subjects)

- Naive to FDA- approved MS therapies such as glatiramer acetate, interferon-beta,
natalizumab, fingolimod, tecfidera, or teriflunomide

Exclusion Criteria:

- Secondary or primary progressive MS

- Prior exposure to FDA-approved MS therapies or chemotherapies of any kind

- Known history of autoimmune disease besides MS

- Known history of renal disease, hypertension or congestive heart failure

- Currently taking medications that could affect urine sodium excretion (e.g. diuretics
or others that act on the renin-angiotensins-aldosterone system)
We found this trial at
1
site
New Haven, Connecticut 06519
Principal Investigator: David Hafler, MD
Phone: 203-737-7095
?
mi
from
New Haven, CT
Click here to add this to my saved trials